 NEW YORK, Dec. 14, 2020 GLOBE NEWSWIRE -- Cellectis S.A. Paris:ALCLS NASDAQ:CLLS NASDAQ: CLLS EURONEXT GROWTH: ALCLS, a clinical-stage biopharmaceutical company focused on developing immunotherapies based on gene-edited allogeneic CAR T-cells, today announced the launch, subject to market conditions, of an underwritten public offering of 100 million of its American Depositary Shares ADS, each representing one ordinary share of Cellectis. In connection with the offering, Cellectis expects to grant the underwriters a 30-day option to purchase up to an additional 15 of the aggregate offering size on the same terms and conditions. 